請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/28935完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 林欽塘(Chin-Tarng Lin) | |
| dc.contributor.author | Ching-Wei Lin | en |
| dc.contributor.author | 林敬瑋 | zh_TW |
| dc.date.accessioned | 2021-06-13T00:30:24Z | - |
| dc.date.available | 2010-08-08 | |
| dc.date.copyright | 2007-08-08 | |
| dc.date.issued | 2007 | |
| dc.date.submitted | 2007-07-26 | |
| dc.identifier.citation | References
Baxter, R.C. (2001). Inhibition of the insulin-like growth factor (IGF)-IGF-binding protein interaction. Hormone research 55 Suppl 2, 68-72. Baylin, S.B., and Herman, J.G. (2000). DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet 16, 168-174. Bell, K.A., and Kurman, R.J. (2000). A clinicopathologic analysis of atypical proliferative (borderline) tumors and well-differentiated endometrioid adenocarcinomas sof the ovary. The American journal of surgical pathology 24, 1465-1479. Bourdon, J.C., Deguin-Chambon, V., Lelong, J.C., Dessen, P., May, P., Debuire, B., and May, E. (1997). Further characterisation of the p53 responsive element--identification of new candidate genes for trans-activation by p53. Oncogene 14, 85-94. Buckbinder, L., Talbott, R., Velasco-Miguel, S., Takenaka, I., Faha, B., Seizinger, B.R., and Kley, N. (1995). Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature 377, 646-649. Butt, A.J., Firth, S.M., King, M.A., and Baxter, R.C. (2000). Insulin-like growth factor-binding protein-3 modulates expression of Bax and Bcl-2 and potentiates p53-independent radiation-induced apoptosis in human breast cancer cells. The Journal of biological chemistry 275, 39174-39181. Chang, Y.S., Kong, G., Sun, S., Liu, D., El-Naggar, A.K., Khuri, F.R., Hong, W.K., and Lee, H.Y. (2002). Clinical significance of insulin-like growth factor-binding protein-3 expression in stage I non-small cell lung cancer. Clin Cancer Res 8, 3796-3802. Chang, Y.S., Wang, L., Suh, Y.A., Mao, L., Karpen, S.J., Khuri, F.R., Hong, W.K., and Lee, H.Y. (2004). Mechanisms underlying lack of insulin-like growth factor-binding protein-3 expression in non-small-cell lung cancer. Oncogene 23, 6569-6580. Chen, C., and Okayama, H. (1987). High-efficiency transformation of mammalian cells by plasmid DNA. Molecular and cellular biology 7, 2745-2752. Clark, S.J., Harrison, J., Paul, C.L., and Frommer, M. (1994). High sensitivity mapping of methylated cytosines. Nucleic acids research 22, 2990-2997. Cubbage, M.L., Suwanichkul, A., and Powell, D.R. (1990). Insulin-like growth factor binding protein-3. Organization of the human chromosomal gene and demonstration of promoter activity. The Journal of biological chemistry 265, 12642-12649. Daskalakis, M., Nguyen, T.T., Nguyen, C., Guldberg, P., Kohler, G., Wijermans, P., Jones, P.A., and Lubbert, M. (2002). Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2'-deoxycytidine (decitabine) treatment. Blood 100, 2957-2964. Deal, C., Ma, J., Wilkin, F., Paquette, J., Rozen, F., Ge, B., Hudson, T., Stampfer, M., and Pollak, M. (2001). Novel promoter polymorphism in insulin-like growth factor-binding protein-3: correlation with serum levels and interaction with known regulators. The Journal of clinical endocrinology and metabolism 86, 1274-1280. Feinberg, A.P. (2001). Cancer epigenetics takes center stage. Proc Natl Acad Sci U S A 98, 392-394. Firth, S.M., and Baxter, R.C. (2002). Cellular actions of the insulin-like growth factor binding proteins. Endocrine reviews 23, 824-854. Flyvbjerg, A., Mogensen, O., Mogensen, B., and Nielsen, O.S. (1997). Elevated serum insulin-like growth factor-binding protein 2 (IGFBP-2) and decreased IGFBP-3 in epithelial ovarian cancer: correlation with cancer antigen 125 and tumor-associated trypsin inhibitor. The Journal of clinical endocrinology and metabolism 82, 2308-2313. Fowler, C.A., Perks, C.M., Newcomb, P.V., Savage, P.B., Farndon, J.R., and Holly, J.M. (2000). Insulin-like growth factor binding protein-3 (IGFBP-3) potentiates paclitaxel-induced apoptosis in human breast cancer cells. International journal of cancer 88, 448-453. Frommer, M., McDonald, L.E., Millar, D.S., Collis, C.M., Watt, F., Grigg, G.W., Molloy, P.L., and Paul, C.L. (1992). A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proceedings of the National Academy of Sciences of the United States of America 89, 1827-1831. Gardiner-Garden, M., and Frommer, M. (1987). CpG islands in vertebrate genomes. Journal of molecular biology 196, 261-282. Giovannucci, E. (1999). Insulin-like growth factor-I and binding protein-3 and risk of cancer. Hormone research 51 Suppl 3, 34-41. Goldberg, A.D., Allis, C.D., and Bernstein, E. (2007). Epigenetics: a landscape takes shape. Cell 128, 635-638. Goll, M.G., and Bestor, T.H. (2005). Eukaryotic cytosine methyltransferases. Annual review of biochemistry 74, 481-514. Gomes, C.P., and Andrade, L.A. (2006). PTEN and p53 expression in primary ovarian carcinomas: immunohistochemical study and discussion of pathogenetic mechanisms. Int J Gynecol Cancer 16 Suppl 1, 254-258. Goodman, M.T., Correa, C.N., Tung, K.H., Roffers, S.D., Cheng Wu, X., Young, J.L., Jr., Wilkens, L.R., Carney, M.E., and Howe, H.L. (2003). Stage at diagnosis of ovarian cancer in the United States, 1992-1997. Cancer 97, 2648-2659. Hainaut, P., and Hollstein, M. (2000). p53 and human cancer: the first ten thousand mutations. Advances in cancer research 77, 81-137. Hanafusa, T., Shinji, T., Shiraha, H., Nouso, K., Iwasaki, Y., Yumoto, E., Ono, T., and Koide, N. (2005). Functional promoter upstream p53 regulatory sequence of IGFBP3 that is silenced by tumor specific methylation. BMC cancer 5, 9. Hanafusa, T., Yumoto, Y., Nouso, K., Nakatsukasa, H., Onishi, T., Fujikawa, T., Taniyama, M., Nakamura, S., Uemura, M., Takuma, Y., et al. (2002). Reduced expression of insulin-like growth factor binding protein-3 and its promoter hypermethylation in human hepatocellular carcinoma. Cancer letters 176, 149-158. Hayatsu, H., Wataya, Y., Kai, K., and Iida, S. (1970). Reaction of sodium bisulfite with uracil, cytosine, and their derivatives. Biochemistry 9, 2858-2865. Herman, J.G., Graff, J.R., Myohanen, S., Nelkin, B.D., and Baylin, S.B. (1996). Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proceedings of the National Academy of Sciences of the United States of America 93, 9821-9826. Hochscheid, R., Jaques, G., and Wegmann, B. (2000). Transfection of human insulin-like growth factor-binding protein 3 gene inhibits cell growth and tumorigenicity: a cell culture model for lung cancer. The Journal of endocrinology 166, 553-563. Jiang, X., Morland, S.J., Hitchcock, A., Thomas, E.J., and Campbell, I.G. (1998). Allelotyping of endometriosis with adjacent ovarian carcinoma reveals evidence of a common lineage. Cancer research 58, 1707-1712. Jones, J.I., and Clemmons, D.R. (1995). Insulin-like growth factors and their binding proteins: biological actions. Endocrine reviews 16, 3-34. Jones, P.A., and Baylin, S.B. (2002). The fundamental role of epigenetic events in cancer. Nat Rev Genet 3, 415-428. Katsaros, D., Fracchioli, S., Arese, P., Enria, R., Cassinelli, P., Mingrone, K., Piccinno, R., Rigault de la Longrais, I.A., and Massobrio, M. (1999). [Chemoresistance in ovarian cancer. State of the art and future prospects]. Minerva ginecologica 51, 483-499. Larsen, F., Gundersen, G., Lopez, R., and Prydz, H. (1992). CpG islands as gene markers in the human genome. Genomics 13, 1095-1107. Li, L.C., and Dahiya, R. (2002). MethPrimer: designing primers for methylation PCRs. Bioinformatics (Oxford, England) 18, 1427-1431. Lukanova, A., Lundin, E., Toniolo, P., Micheli, A., Akhmedkhanov, A., Rinaldi, S., Muti, P., Lenner, P., Biessy, C., Krogh, V., et al. (2002). Circulating levels of insulin-like growth factor-I and risk of ovarian cancer. International journal of cancer 101, 549-554. Oh, Y., Muller, H.L., Lamson, G., and Rosenfeld, R.G. (1993). Insulin-like growth factor (IGF)-independent action of IGF-binding protein-3 in Hs578T human breast cancer cells. Cell surface binding and growth inhibition. The Journal of biological chemistry 268, 14964-14971. Paulsen, M., and Ferguson-Smith, A.C. (2001). DNA methylation in genomic imprinting, development, and disease. The Journal of pathology 195, 97-110. Rajah, R., Valentinis, B., and Cohen, P. (1997). Insulin-like growth factor (IGF)-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-beta1 on programmed cell death through a p53- and IGF-independent mechanism. The Journal of biological chemistry 272, 12181-12188. Ricort, J.M., Lombet, A., Lassarre, C., and Binoux, M. (2002). Insulin-like growth factor binding protein-3 increases intracellular calcium concentrations in MCF-7 breast carcinoma cells. FEBS letters 527, 293-297. Robertson, K.D. (2001). DNA methylation, methyltransferases, and cancer. Oncogene 20, 3139-3155. Rocha, R.L., Hilsenbeck, S.G., Jackson, J.G., VanDenBerg, C.L., Weng, C., Lee, A.V., and Yee, D. (1997). Insulin-like growth factor binding protein-3 and insulin receptor substrate-1 in breast cancer: correlation with clinical parameters and disease-free survival. Clin Cancer Res 3, 103-109. Shapiro, R., and Weisgras, J.M. (1970). Bisulfite-catalyzed transamination of cytosine and cytidine. Biochemical and biophysical research communications 40, 839-843. Shih Ie, M., and Kurman, R.J. (2004). Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. The American journal of pathology 164, 1511-1518. Simpson, J.L., and Bischoff, F.Z. (2002). Heritability and molecular genetic studies of endometriosis. Annals of the New York Academy of Sciences 955, 239-251; discussion 293-235, 396-406. Stewart, C.E., and Rotwein, P. (1996). Growth, differentiation, and survival: multiple physiological functions for insulin-like growth factors. Physiological reviews 76, 1005-1026. Takaoka, M., Harada, H., Andl, C.D., Oyama, K., Naomoto, Y., Dempsey, K.L., Klein-Szanto, A.J., El-Deiry, W.S., Grimberg, A., and Nakagawa, H. (2004). Epidermal growth factor receptor regulates aberrant expression of insulin-like growth factor-binding protein 3. Cancer research 64, 7711-7723. Tate, P.H., and Bird, A.P. (1993). Effects of DNA methylation on DNA-binding proteins and gene expression. Current opinion in genetics & development 3, 226-231. Tomii, K., Tsukuda, K., Toyooka, S., Dote, H., Hanafusa, T., Asano, H., Naitou, M., Doihara, H., Kisimoto, T., Katayama, H., et al. (2007). Aberrant promoter methylation of insulin-like growth factor binding protein-3 gene in human cancers. International journal of cancer 120, 566-573. Torng, P.L., Mao, T.L., Chan, W.Y., Huang, S.C., and Lin, C.T. (2004). Prognostic significance of stromal metalloproteinase-2 in ovarian adenocarcinoma and its relation to carcinoma progression. Gynecologic oncology 92, 559-567. Wiley, A., Katsaros, D., Chen, H., Rigault de la Longrais, I.A., Beeghly, A., Puopolo, M., Singal, R., Zhang, Y., Amoako, A., Zelterman, D., et al. (2006a). Aberrant promoter methylation of multiple genes in malignant ovarian tumors and in ovarian tumors with low malignant potential. Cancer 107, 299-308. Wiley, A., Katsaros, D., Fracchioli, S., and Yu, H. (2006b). Methylation of the insulin-like growth factor binding protein-3 gene and prognosis of epithelial ovarian cancer. Int J Gynecol Cancer 16, 210-218. Yamashita, S., Tsujino, Y., Moriguchi, K., Tatematsu, M., and Ushijima, T. (2006). Chemical genomic screening for methylation-silenced genes in gastric cancer cell lines using 5-aza-2'-deoxycytidine treatment and oligonucleotide microarray. Cancer science 97, 64-71. Youssef, E.M., Chen, X.Q., Higuchi, E., Kondo, Y., Garcia-Manero, G., Lotan, R., and Issa, J.P. (2004). Hypermethylation and silencing of the putative tumor suppressor Tazarotene-induced gene 1 in human cancers. Cancer research 64, 2411-2417. Yu, H., and Berkel, H. (1999). Insulin-like growth factors and cancer. J La State Med Soc 151, 218-223. Yu, w.-m. (1996). The mutation spectrum of p53 gene in breast cancer from Taiwan. In graduate institute of pathology (Taipei, Taiwan university). Zi, X., Zhang, J., Agarwal, R., and Pollak, M. (2000). Silibinin up-regulates insulin-like growth factor-binding protein 3 expression and inhibits proliferation of androgen-independent prostate cancer cells. Cancer research 60, 5617-5620. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/28935 | - |
| dc.description.abstract | 胰島素生長因子結合蛋白-3(IGFBP-3)藉由和胰島素生長因子之結合,在體內執行抑制細胞生長的功能.在本實驗室之前的研究中,我們利用卵巢癌侵襲模型(Ovarial cancer invasion model)來建立卵巢類子宮內膜腺癌細胞株(ovarian endometrioid carcinoma) OVTW59的分株(P0~P4)。藉著互補去氧核糖核酸微矩陣(cDNA microarray)和及時定量聚合酶鍊反應(Real-time RT PCR),我們發現由P0到P4其細胞株之IGFBP-3的基因表現由高到低有顯著差異。在一系列體外(in vitro)及動物實驗的功能性分析顯示,IGFBP-3能夠抑制卵巢類子宮內膜腺癌細胞的移動、侵襲以及轉移的能力,並可誘發癌細胞的凋亡,證明IGFBP-3有抑癌基因的特色。在本實驗中,我們利用卵巢類子宮內膜腺癌細胞株P0以及P4作為模型,去探討IGFBP-3 的表現是否受到其基因啟動區(promoter region)的甲基化(methylation)而抑制其基因的表現。經過去甲基化藥物5’-aza-dC的處理過後,P4的mRNA以及蛋白的表現量有顯著回升的情形。同時,我們利用亞硫酸定序及專一性甲基化聚合酶鍊反應來分析卵巢類子宮內膜腺癌細胞株以及60個臨床檢體的IGFBP-3基因啟動區(promoter region)之甲基化情形。發現在卵巢類子宮內膜腺癌中, 40.43% 病人IGFBP-3基因啟動區(promoter region)有過度甲基化的情形;並且在細胞模型中,我們發現IGFBP-3甲基化靜默的現象是透過IGFBP-3基因啟動區上p53轉錄因子(transcription factor)結合位置的過度甲基化,進而影響了p53 調控IGFBP-3的轉錄活性所導致。以上研究顯示, IGFBP-3基因啟動區(promoter region)過度甲基化為影響其基因表達的一個調控機制。 | zh_TW |
| dc.description.abstract | Insulin growth factor binding protein-3 (IGFBP-3) functions as a carrier of insulin-like growth factors (IGFs) in vascular circulation and has been postulated to be a mediator of growth suppression signal in cells. In our previously study, IGFBP-3 was selected from the cDNA microarray analysis of the progressive increase in invasion capability of ovarian endometrioid carcinoma cancer cell line OVTW59 sublines P0 to P4, its expression is very low in the advanced cancer cells such as P4 cell line. It has been proved as a tumor suppressor to inhibit tumor cell migration, invasion and metastasis and induce apoptosis in ovarian cancer pathogenesis. Since promoter CpG island hypermethylation can silence gene expression, we investigated whether hypermethylation of the IGFBP-3 promoter is involved in loss of IGFBP-3 expression in ovarian endometrioid carcinoma. After treatment with DNA methyltransferase inhibitor 5’-aza-2-deoxycytidine for eight days, restored expression of IGFBP-3 mRNA transcript was found in ovarian cancer cell line P4. In addition, we examined the methylation status of IGFBP-3 by methylation-specific PCR (MSP) assay and bisulfite genomic DNA sequencing, The methylation status correlated with IGFBP-3 mRNA and protein expression levels in endometrioid carcinoma cell lines. Furthermore, we analyzed 60 clinical samples and found that IGFBP-3 promoter was hypermethylated in 40.43% of ovarian endometrioid carcinoma surgical specimens. Moreover, we also found the hyprermethylated CpG sites of -210,-206,-183 and -179 in p53 consensus binding region in IGFBP-3 promoter may play a critical role in the effect of its promoter activity, These findings indicate that the silenced IGFBP-3 expression in advanced P4 line and patients is primarily regulated IGFBP-3 promoter region by hypermethylation in the p53 binding region. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-13T00:30:24Z (GMT). No. of bitstreams: 1 ntu-96-R94444002-1.pdf: 4138571 bytes, checksum: 150f969051db3d68566f077b6f284eb6 (MD5) Previous issue date: 2007 | en |
| dc.description.tableofcontents | 中文摘要1
Abstract 2 Introduction3 Materials and Methods9 Results 19 Discussions 25 Tables 31 Figures 36 References 51 | |
| dc.language.iso | en | |
| dc.subject | IGFBP-3 | zh_TW |
| dc.subject | 卵巢癌 | zh_TW |
| dc.subject | methylation | en |
| dc.subject | IGFBP-3 | en |
| dc.subject | ovarian cancer | en |
| dc.title | IGFBP-3基因表達在卵巢類子宮內膜腺癌中之分子調控機制 | zh_TW |
| dc.title | Molecular regulatory mechanism ofIGFBP-3 expression in ovarian endometrioid carcinoma | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 95-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 童寶玲,吳漢中,黃奇英,李明學 | |
| dc.subject.keyword | IGFBP-3,卵巢癌, | zh_TW |
| dc.subject.keyword | IGFBP-3,methylation,ovarian cancer, | en |
| dc.relation.page | 56 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2007-07-26 | |
| dc.contributor.author-college | 醫學院 | zh_TW |
| dc.contributor.author-dept | 病理學研究所 | zh_TW |
| 顯示於系所單位： | 病理學科所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-96-1.pdf 未授權公開取用 | 4.04 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。